Rubraca Unia Europejska - polski - EMA (European Medicines Agency)

rubraca

pharmaand gmbh - rucaparib camsylate - nowotwory jajnika - Środki przeciwnowotworowe - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca jest wskazany w monoterapii w leczeniu dorosłych pacjentów z платиночувствительный nawrotu wysokiej jakości nabłonka jajnika, jajowodu lub pierwotnym перитонеальным na raka, którzy w odpowiedzi (pełny lub częściowy) na bazie platyny chemioterapii.

Yescarta Unia Europejska - polski - EMA (European Medicines Agency)

yescarta

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - Środki przeciwnowotworowe - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Elzonris Unia Europejska - polski - EMA (European Medicines Agency)

elzonris

stemline therapeutics b.v. - tagraxofusp - lymphoma - Środki przeciwnowotworowe - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).